Screener
Polaryx Therapeutics, Inc. PLYX Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Net operating loss carryforwards | $4,742 | $4,096 |
| Gene therapy patent license | 852 | — |
| Credits | 50 | 19 |
| Capitalized research and development | 998 | 1,217 |
| Total deferred tax assets | 6,642 | 5,332 |
| Valuation allowance | (6,392) | (4,865) |
| Net deferred tax assets | $250 | $467 |
| Deferred tax liabilities |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s deferred tax assets?
- Polaryx Therapeutics, Inc. (PLYX) reported deferred tax assets of $4.74M in Q4 2025.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Polaryx Therapeutics, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude